



Resource impact statement

Resource impact

Published: 3 November 2021

www.nice.org.uk

Cancer Drugs Fund technology

NICE has recommended selpercatinib for use within the Cancer Drugs Fund as an option for treating:

- advanced RET fusion-positive thyroid cancer in adults who need systemic therapy after sorafenib or lenvatinib
- advanced RET-mutant medullary thyroid cancer in people 12 years and older who need systemic therapy after cabozantinib or vandetanib.

It is recommended only if the conditions in the managed access agreement are followed.

Selpercatinib will be available to the NHS in line with the [managed access agreement](#) with NHS England. As part of this, NHS England and Eli Lilly and Company have a commercial access agreement that makes selpercatinib available to the NHS at a reduced cost. The financial terms of the agreement are commercial in confidence.

It is estimated that around 60 people with advanced RET-fusion positive thyroid cancer and 10 people with advanced RET-mutant medullary thyroid cancer in the first year (prevalent cases) will be eligible for treatment with selpercatinib. In subsequent years, around 10 newly diagnosed people per year with advanced RET-fusion positive thyroid cancer and 1 newly diagnosed person per year with advanced RET-mutant positive medullary thyroid cancer will be eligible for treatment with selpercatinib.

The resource impact of selpercatinib will be covered by the Cancer Drugs Fund budget. Selpercatinib could be cost effective if more data becomes available from the LIBRETTO-001 trial that shows people live longer with treatment. Data from the trial and NHS practice would also help address the uncertainty about its clinical effectiveness. Selpercatinib is therefore recommended for use in the Cancer Drugs Fund so that more evidence can be collected. After this, NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then. Further information can be found in [NHS England's Appraisal and Funding of Cancer Drugs from July 2016 \(including the new Cancer Drugs Fund\) - A new deal for patients, taxpayers and industry](#).

This technology is commissioned by NHS England. Providers are NHS hospital trusts.